Dr. Robert J. Hopkin, MD

Dr. Hopkin practices at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio, part of Cincinnati Children's Hospital Medical Center.

Dr. Hopkin's NPI, 1447281878, was assigned on July 5, 2006. Dr. Hopkin graduated from University of Nevada School of Medicine in 1990. Dr. Hopkin holds Ohio license 35.066579.

Dr. Hopkin's primary practice is Cincinnati Children's Hospital Medical Center, at 3333 Burnet Avenue, Cincinnati, OH 45229 in Hamilton County. The practice phone is (513) 636-3333.

Dr. Hopkin's primary practice is Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio, part of Cincinnati Children's Hospital Medical Center. The medical group on file is Cincinnati Children's. Dmand AI also links Dr. Hopkin to 1 more dialysis center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hopkin practices, 3 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Hopkin's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Hopkin is licensed in Ohio.

CMS data shows 14 Medicare services from Dr. Hopkin across 1 procedure code in 2022, all of them office visits, for 14 Medicare patients. Medicare paid $1,476 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 14 Medicare patients who saw Dr. Hopkin in 2024. The largest group is 85 and over, with 0 patients. Their average risk score is 3.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hopkin's median patient age at 12, with 51% women.

In 2024, Dr. Hopkin wrote 110 Medicare Part D claims for 11 patients. CMS names the drug for 95 of them, across 3 drugs with 11 or more claims each, at $2,145,730 in total drug cost. In 2023, CMS named 135 claims across 2 drugs.

Dr. Hopkin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 121 papers to Dr. Hopkin, published from 2010 to 2025. 2019 was the busiest year, with 11. The most frequent topics are Fabry Disease, alpha-Galactosidase and Phenotype. Dr. Hopkin has published most often in Am J Med Genet A. Dr. Hopkin's most frequent co-authors are Carlos Enrique Prada, MD, Beth M. Kline-Fath and Rachel C. Lombardo, MD.

Dmand AI links Dr. Hopkin to 7 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Fabry Disease, Cerebral Small Vessel Diseases and Angiokeratoma. Genzyme, a Sanofi Company sponsors the most, 2. Open Payments lists research payments to Dr. Hopkin that name 3 trials.

CMS Open Payments shows 511 general payments to Dr. Hopkin from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 37% of the total. Sanofi and Genzyme US Companies paid the most, $384,057. It also lists 16 research payments totaling $6,031 from 2017 to 2023, naming 3 clinical trials.

Dr. Hopkin graduated from University of Nevada School of Medicine in 1990.